Eton Pharmaceuticals receives FDA approval for DESMODA oral solution for central diabetes insipidus

Eton Pharmaceuticals, Inc.

FDA approved DESMODA (desmopressin acetate) Oral Solution for central diabetes insipidus in all ages; first approved oral liquid formulation.
Commercial launch expected March 9; product available exclusively through Anovo specialty pharmacy.
Eton estimates >13,000 U.S. patients; potential peak sales of $30-$50M annually.
Patent protection through 2044; product leverages existing pediatric endocrinology rare disease sales team.
Key safety warning: risk of hyponatremia; fluid restriction recommended; contraindicated in moderate to severe renal impairment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.